Christine M Lovly

Christine M Lovly

UNVERIFIED PROFILE

Are you Christine M Lovly?   Register this Author

Register author
Christine M Lovly

Christine M Lovly

Publications by authors named "Christine M Lovly"

Are you Christine M Lovly?   Register this Author

75Publications

2286Reads

27Profile Views

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

J Thorac Oncol 2019 Aug 22. Epub 2019 Aug 22.

Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN 37232; Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Nashville, TN 37232.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.08.003DOI Listing
August 2019

Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes.

J Thorac Oncol 2019 Jun 12. Epub 2019 Jun 12.

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.05.042DOI Listing
June 2019

Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases.

J Thorac Oncol 2019 Mar 10;14(3):e45-e48. Epub 2018 Dec 10.

Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382512PMC
March 2019

Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.

J Thorac Oncol 2019 Feb;14(2):e29-e30

City of Hope Comprehensive Cancer Center, Duarte, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.169DOI Listing
February 2019

Quantifying Drug Combination Synergy along Potency and Efficacy Axes.

Cell Syst 2019 Feb 20;8(2):97-108.e16. Epub 2019 Feb 20.

Center for Cancer Systems Biology at Vanderbilt, Vanderbilt University, Nashville, TN 37232, USA; Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cels.2019.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675406PMC
February 2019

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Mol Cancer Res 2018 11 12;16(11):1724-1736. Epub 2018 Jul 12.

Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-18-0171DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214753PMC
November 2018

Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.

Cancer Discov 2018 07;8(7):797-799

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0489DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345252PMC
July 2018

Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:726-739

From the Department of Medicine, Memorial Sloan Kettering Cancer Center, Weil Cornell Medical College, New York, NY; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_201331DOI Listing
May 2018

Established, emerging and elusive molecular targets in the treatment of lung cancer.

J Pathol 2018 04 14;244(5):565-577. Epub 2018 Feb 14.

Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5038DOI Listing
April 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

Mechanisms of receptor tyrosine kinase activation in cancer.

Mol Cancer 2018 02 19;17(1):58. Epub 2018 Feb 19.

Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-018-0782-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817791PMC
February 2018

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.

J Thorac Oncol 2018 01 23;13(1):112-123. Epub 2017 Sep 23.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.09.1951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827950PMC
January 2018

Managing Resistance to EFGR- and ALK-Targeted Therapies.

Am Soc Clin Oncol Educ Book 2017 ;37:607-618

From the Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN; Department of Radiation Oncology, Thoracic Disease Oriented Team, Thoracic Radiation Oncology Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX; Harvard Medical School, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_176251DOI Listing
November 2017

Tumor Heterogeneity and Therapeutic Resistance.

Am Soc Clin Oncol Educ Book 2016 ;35:e585-93

From the Department of Medicine, Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN; Department of Internal Medicine, Duke University Medical Center, Durham, NC; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_158808DOI Listing
January 2017

Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer.

Cancer Discov 2016 10;6(10):1084-1086

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0910DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117458PMC
October 2016

My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information.

AMIA Jt Summits Transl Sci Proc 2016 20;2016:112-21. Epub 2016 Jul 20.

Knowledge Management, Vanderbilt University Medical Center, Nashville, TN;; Department of Biomedical Informatics & Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN;

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001739PMC
August 2016

Major milestones in translational oncology.

BMC Med 2016 07 28;14(1):110. Epub 2016 Jul 28.

Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12916-016-0654-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964079PMC
July 2016

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

Cancer J 2015 Sep-Oct;21(5):378-82

From the Departments of *Medicine and †Cancer Biology, Vanderbilt University Medical Center, and ‡Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242382PMC
June 2016

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Cancer Discov 2016 06 21;6(6):601-11. Epub 2016 Apr 21.

Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. Addario Lung Cancer Medical Institute, Cambridge, Massachusetts. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893907PMC
June 2016

Melanoma driver mutations and immune therapy.

Oncoimmunology 2016 May 10;5(5):e1051299. Epub 2016 Mar 10.

Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center , Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1051299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910708PMC
May 2016

The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome.

Transl Oncol 2016 Apr;9(2):163-165

Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, 37232; Department of Medicine, Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN, 37232; Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, 37232. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2016.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833964PMC
April 2016

Combating acquired resistance to tyrosine kinase inhibitors in lung cancer.

Am Soc Clin Oncol Educ Book 2015 :e165-73

From the Division of Hematology-Oncology, Vanderbilt University School of Medicine, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e165DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734636PMC
February 2016

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.

Lung Cancer 2016 Feb 10;92:29-34. Epub 2015 Nov 10.

Department of Medicine/Division of Hematology-Oncology, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN 37232, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.11.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874190PMC
February 2016

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.

J Clin Oncol 2016 Jan 5;34(2):123-9. Epub 2015 Oct 5.

Kimberly L. Johung, Sarah Goldberg, James B. Yu, Veronica L. Chiang, and Joseph N. Contessa, Yale University School of Medicine, New Haven, CT; Norman Yeh, Brian D. Kavanagh, and D. Ross Cambidge, University of Colorado Comprehensive Cancer Center, Aurora, CO; Neil B. Desai and Kathryn Beal, Memorial Sloan Kettering Cancer Center, New York, NY; Terence M. Williams and Tim Lautenschlaeger, Ohio State University, Columbus, OH; Nils D. Arvold, Dana-Farber/Brigham and Women's Hospital, Boston, MA; and Matthew S. Ning, Albert Attia, and Christine M. Lovly, Vanderbilt University School of Medicine, Nashville, TN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/09/29/JCO.2015.62
Web Search
http://jco.ascopubs.org/content/34/2/123.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.62.0138
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.0138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070549PMC
January 2016

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

Cancer Res 2016 Jan 7;76(2):305-18. Epub 2016 Jan 7.

Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee. Division of Rheumatology and Immunology, Vanderbilt University, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee. Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/early/2016/01/07/0
Web Search
http://cancerres.aacrjournals.org/content/early/2016/01/07/0
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-15-0717DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715957PMC
January 2016

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.

Cancer Discov 2015 Nov 18;5(11):1155-63. Epub 2015 Aug 18.

Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0654DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631701PMC
November 2015

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.

Clin Cancer Res 2015 Oct;21(19):4270-7

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/21/19/4270.ful
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-2518DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593065PMC
October 2015

Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors.

Nat Med 2015 Jul;21(7):663-5

Department of Cancer Biology and the Department of Medicine, Vanderbilt University School of Medicine and Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3899DOI Listing
July 2015

Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer.

Cancer Discov 2015 Jul;5(7):694-6

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0616DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499857PMC
July 2015

Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.

Mod Pathol 2015 May 23;28(5):732-9. Epub 2015 Jan 23.

1] Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN, USA [2] Department of Medicine, Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2014.165DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874150PMC
May 2015

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.

Cancer Immunol Res 2015 May 3;3(5):464-9. Epub 2015 Feb 3.

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420706PMC
May 2015

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Clin Cancer Res 2015 May;21(10):2227-35

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2791DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435823PMC
May 2015

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.

Clin Cancer Res 2015 Apr 28;21(8):1935-43. Epub 2014 Oct 28.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401580PMC
April 2015

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

J Thorac Oncol 2015 Mar;10(3):431-7

*Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, †Department of Epidemiology and Biostatistics, ‡Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; §Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA; ‖Department of Medicine, Vanderbilt Ingram Cancer Center, Franklin, TN; and ¶Lowe center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479120PMC
March 2015

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.

Mol Cancer Ther 2015 Feb 4;14(2):542-52. Epub 2014 Dec 4.

Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee. Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee. Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338015PMC
February 2015

Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.

Clin Cancer Res 2014 Dec 10;20(23):5898-907. Epub 2014 Oct 10.

Department of Medicine, Vanderbilt University School of Medicine and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-2437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253858PMC
December 2014

Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Clin Cancer Res 2014 May 5;20(9):2264-75. Epub 2014 Mar 5.

Authors' Affiliations: Departments of Cancer Biology, Medicine, Biomedical Informatics, and Pathology, Microbiology, and Immunology; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008689PMC
May 2014

Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.

Clin Cancer Res 2014 May;20(9):2249-56

Authors' Affiliations: Department of Medicine, Vanderbilt University School of Medicine and Vanderbilt Ingram Cancer Center, Nashville, Tennessee; and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1610DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029617PMC
May 2014

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.

J Natl Compr Canc Netw 2014 Jan;12(1):6-11; quiz 11

From the Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151469PMC
http://dx.doi.org/10.6004/jnccn.2014.0002DOI Listing
January 2014

Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.

Curr Treat Options Oncol 2012 Dec;13(4):516-26

Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, 2220 Pierce Avenue South, 777 Preston Research Building, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-012-0204-6
Publisher Site
http://dx.doi.org/10.1007/s11864-012-0204-6DOI Listing
December 2012

Translating genomic information into clinical medicine: lung cancer as a paradigm.

Genome Res 2012 Nov 27;22(11):2101-8. Epub 2012 Sep 27.

Department of Biomedical Informatics, Vanderbilt University Medical School, Nashville, TN 37212, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/gr.131128.111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483539PMC
November 2012

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

Clin Cancer Res 2012 Sep 21;18(17):4682-90. Epub 2012 Aug 21.

Department of Translational Genomics, University of Cologne, c/o MPI for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-3260DOI Listing
September 2012

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

Sci Transl Med 2012 Feb;4(120):120ps2

Department of Medicine, Division of Hematology and Oncology, Vanderbilt University, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://stm.sciencemag.org/cgi/doi/10.1126/scitranslmed.30037
Publisher Site
http://dx.doi.org/10.1126/scitranslmed.3003728DOI Listing
February 2012

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Clin Cancer Res 2011 Dec 26;17(23):7394-401. Epub 2011 Sep 26.

Max Planck Institute for Neurological Research, Klaus-Joachim-Zülch Laboratories of the Max Planck Society, Köln, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382103PMC
December 2011

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

Cancer Res 2011 Jul 25;71(14):4920-31. Epub 2011 May 25.

Departments of Medicine and Biostatistics, Vanderbilt University, Nashville, Tennessee, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-3879DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138877PMC
July 2011

Lung cancer in 2010: One size does not fit all.

Nat Rev Clin Oncol 2011 Feb;8(2):68-70

Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, Preston Research Building 685, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2010.224DOI Listing
February 2011

Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379.

Mol Cell Biol 2008 Oct 21;28(19):5874-85. Epub 2008 Jul 21.

Department of Cell Biology and Physiology, Washington University School of Medicine, Box 8228, 660 S. Euclid Ave., St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.00821-08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547006PMC
October 2008

Identification of protein phosphorylation sites within Ser/Thr-rich cluster domains using site-directed mutagenesis and hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometry.

Rapid Commun Mass Spectrom 2007 ;21(21):3443-51

Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rcm.3223DOI Listing
December 2007

The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas.

Proc Natl Acad Sci U S A 2006 Jun 2;103(24):9220-5. Epub 2006 Jun 2.

Division of Molecular Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.0507809103
Publisher Site
http://dx.doi.org/10.1073/pnas.0507809103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1482593PMC
June 2006

Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase.

Anal Chem 2006 Apr;78(7):2171-81

Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ac051520lDOI Listing
April 2006

Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation.

Mol Cancer Res 2003 Jun;1(8):598-609

Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
June 2003